GRACEcast
Highlights in Lung Cancer, 2013: MEK Inhibitors for KRAS Mutation-Positive NSCLC (audio)
- Author: Podcast
- Narrator: Podcast
- Publisher: Podcast
- Duration: 0:05:27
- More information
Informações:
Synopsis
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.
